Total Valuation
Pharma Mar SA has a market cap or net worth of $1.66B. The enterprise value is $1.40K.
Market Cap$1.66B
Enterprise Value$1.40K
Share Statistics
Pharma Mar SA has 18,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,000,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Pharma Mar SA’s return on equity (ROE) is 0.30 and return on invested capital (ROIC) is 12.83%.
Return on Equity (ROE)0.30
Return on Assets (ROA)0.19
Return on Invested Capital (ROIC)12.83%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee438.40K
Profits Per Employee118.12K
Employee Count505
Asset Turnover0.56
Inventory Turnover0.24
Valuation Ratios
The current PE Ratio of Pharma Mar SA is 16.9. Pharma Mar SA’s PEG ratio is 0.09.
PE Ratio16.9
PS Ratio5.82
PB Ratio5.12
Price to Fair Value5.12
Price to FCF29.46
Price to Operating Cash Flow22.03
PEG Ratio0.09
Income Statement
In the last 12 months, Pharma Mar SA had revenue of 221.39M and earned 74.99M in profits. Earnings per share was 4.30.
Revenue221.39M
Gross Profit209.13M
Operating Income40.28M
Pretax Income59.65M
Net Income74.99M
EBITDA48.30M
Earnings Per Share (EPS)4.30
Cash Flow
In the last 12 months, operating cash flow was 62.21M and capital expenditures -11.11M, giving a free cash flow of 51.10M billion.
Operating Cash Flow62.21M
Free Cash Flow51.10M
Free Cash Flow per Share2.84
Dividends & Yields
Pharma Mar SA pays an annual dividend of $1.139, resulting in a dividend yield of 1.23%
Dividend Per Share$1.139
Dividend Yield1.23%
Payout Ratio21.61%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.65
52-Week Price Change2.44%
50-Day Moving Average92.59
200-Day Moving Average92.98
Relative Strength Index (RSI)52.14
Average Volume (3m)37.00
Important Dates
Pharma Mar SA upcoming earnings date is Nov 4, 2026, TBA (Confirmed).
Last Earnings DateJul 29, 2026
Next Earnings DateNov 4, 2026
Ex-Dividend Date―
Financial Position
Pharma Mar SA as a current ratio of 3.02, with Debt / Equity ratio of 18.28%
Current Ratio3.02
Quick Ratio2.48
Debt to Market Cap0.04
Net Debt to EBITDA0.65
Interest Coverage Ratio16.38
Taxes
In the past 12 months, Pharma Mar SA has paid -15.34M in taxes.
Income Tax-15.34M
Effective Tax Rate-0.26
Enterprise Valuation
Pharma Mar SA EV to EBITDA ratio is 27.34, with an EV/FCF ratio of 30.19.
EV to Sales5.97
EV to EBITDA27.34
EV to Free Cash Flow30.19
EV to Operating Cash Flow24.86
Balance Sheet
Pharma Mar SA has $168.88M in cash and marketable securities with $45.84M in debt, giving a net cash position of $123.04M billion.
Cash & Marketable Securities$168.88M
Total Debt$45.84M
Net Cash$123.04M
Net Cash Per Share$6.84
Tangible Book Value Per Share$14.43
Margins
Gross margin is 91.54%, with operating margin of 18.19%, and net profit margin of 33.87%.
Gross Margin91.54%
Operating Margin18.19%
Pretax Margin26.94%
Net Profit Margin33.87%
EBITDA Margin21.81%
EBIT Margin18.19%
Analyst Forecast
The average price target for Pharma Mar SA is $115.11, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$115.11
Price Target Upside27.76% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast38.30%
EPS Growth Forecast337.44%